GlicoTech is a spin-off emerged from a joint effort from scientific researches from the Medical Biochemistry Institute of the Federal University of Rio de Janeiro (Brazil) and biotech professionals. This startup was launched with the aim to use a practical business strategy to exploit the market potential of glycobiology related research projects from the Connective Tissue Lab (CTL). GlicoTech is an early stage company open to new financial and technical partnerships seeking the global pharmaceutical market. Glycosaminoglycans (GAGs) are complex sugars that occur in the matrix, cell surface and intracellular space regulating different physiological functions in health and disease conditions. Based on their function within the body, GAGs have diverse therapeutic uses, including as modulators of coagulation, inflammation, infection and cancer. GlycoTech has shorter time-to-market projects for coagulation medications, and more radical innovation projects on the development of drugs for the treatment of cancer and inflammatory diseases. GlicoTech has projects focused on the therapeutic use of glycosaminoglycans (GAGs) with varying MVP times, risk and expected market size. At this early stage major efforts concentrate on the scale-up and NDA submission of a high anticoagulant bovine heparin. Other projects on the discovery/production phase contain the use of heparin-based and marine organism GAGs to treatment of metastasis and inflammation, with a future study of the molecular biology mechanisms of these GAGs biosynthesis targeting future chemical-enzymatic production.